Jan van de Winkel, Ph.D.

About

As the President and Chief Executive Officer of Genmab, an international biotechnology company, which I co-founded in 1999, I’m proud to lead a brilliant and dedicated team of 2,800+ people across our international locations in the Netherlands, Denmark, Germany, the UK, France, the U.S., China and Japan. We are rooted in science, inspired by patients and our goal is to improve the lives of patients by creating and developing innovative and truly differentiated antibody therapies. I have over 30 years of experience in the therapeutic antibody field, authored 300+ scientific publications and am responsible for 180+ patents and patent applications. I hold a Professorship in Immunotherapy at Utrecht University, and am a member of the Board of Directors of Novo Nordisk. Follow me on LinkedIn, as I will share my perspective on the biotech innovation ecosystem and how Genmab is evolving to become a leading biotech innovation powerhouse.8

Experience

• Genmab (Full-time · 27 yrs 5 mos)
  • President & Chief Executive Officer
    Jun 2010 - Present · 16 yrs 1 mo

  • President Research & Development and Chief Scientific Officer
    May 2008 - Jun 2010 · 2 yrs 2 mos

  • Executive Vice President & Chief Scientific Officer
    Jan 2003 - May 2008 · 5 yrs 5 mos

• Utrecht University (Full-time · 38 yrs 2 mos)
  • Professor, Immunotherapy
    Dec 1996 - Present · 29 yrs 7 mos

  • Various Leadership Positions
    May 1988 - Nov 1996 · 8 yrs 7 mos

• Medarex (Full-time · 3 yrs 8 mos)
  • Vice President, Medarex Europe
    Jan 1998 - Jun 2000 · 2 yrs 6 mos

  • Scientific Director, Medarex Europe
    Nov 1996 - Jun 2000 · 3 yrs 8 mos

• Visiting Scientist, Department of Internal Medicine at The Ohio State University
  Jan 1990 - Dec 1990 · 1 yr